Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Transcode Therapeutics Inc (NQ: RNAZ )

0.4800 +0.0150 (+3.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Transcode Therapeutics Inc

< Previous 1 2 3 Next >
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics, Inc. Announces Closing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode shares to remain listed on Nasdaq 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
Highlights TTX-MC138’s Path from Target Discovery to the Clinic 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic... 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.